AngioDynamics Inc (ANGO) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 144 - Report of proposed sale of securities

AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s...

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s...

AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s...

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s...

AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report